Sacco Paola Claudia, Maione Paolo, Rossi Antonio, Sgambato Assunta, Casaluce Francesca, Palazzolo Giovanni, Gridelli Cesare
Division of Medical Oncology, "S.G.Moscati" Hospital, Avellino, Italy.
Curr Pharm Des. 2015;21(32):4763-72. doi: 10.2174/1381612821666150729120009.
Lung cancer is the leading cause of death from cancer worldwide with limited available treatment options in absence of specific molecular alteration. New therapeutic approaches for addressing non small cell lung cancer (NSCLC) are urgently needed. Angiogenesis plays a central role in the tumor growth and metastatic dissemination which stimulates multiple cells to build new abnormal microvessels and leads to tumor microenvironment alterations. This process involves many factors, such as, the vascular endothelial growth factor (VEGF) that has a dominant role, the fibroblast growth factors (FGFs) and the plateled-derived growth factor (PDGF) that together contribute to resistance to VEGF/VEGFR- directed therapy. To date, bevacizumab is currently the only angiogenesis inhibitor that has been approved for the treatment of patients with advanced NSCLC in first-line setting. Moreover, in the last year, two new antiangiogenic agents have been approved for the treatment of patients with advanced NSCLC in second line setting. This review describes the new antiangiogenic agents in the treatment of advanced NSCLC.
肺癌是全球癌症死亡的主要原因，在缺乏特定分子改变的情况下，可用的治疗选择有限。迫切需要针对非小细胞肺癌（NSCLC）的新治疗方法。血管生成在肿瘤生长和转移扩散中起核心作用，它刺激多种细胞构建新的异常微血管，并导致肿瘤微环境改变。这个过程涉及许多因素，例如起主要作用的血管内皮生长因子（VEGF）、成纤维细胞生长因子（FGFs）和血小板衍生生长因子（PDGF），它们共同导致对VEGF/VEGFR靶向治疗产生抗性。迄今为止，贝伐单抗是目前唯一被批准用于一线治疗晚期NSCLC患者的血管生成抑制剂。此外，去年有两种新的抗血管生成药物被批准用于二线治疗晚期NSCLC患者。本综述描述了用于治疗晚期NSCLC的新型抗血管生成药物。
